Product Images Tadalafil

This is a package of Tadalafil Tablets, USP, with a strength of 20mg and contains 15 tablets. The NDC code is 51655-063-54, and it is repackaged by Northwind Pharmaceuticals. The tablets should not be split, and the entire dose should be taken. The package insert should be referred to for dosage. It should be stored at 20° - 25°C (68 - 77°F) and kept out of the reach of children. The GTIN is 0035165063545, and the S/N is 000000000000000. The package is from Lot 0000000000 and the expiration date is 00/00/0000.*

This appears to be a table of blood pressure readings, with systolic and diastolic measurements taken when the subject is standing and supine (lying down). There is also a column that shows the difference in blood pressure between the subject taking Tadalafil and the placebo. The time that the measurements were taken is indicated on the right-hand side of the table.*

This is a chart or graph that shows systolic blood pressure measurements in both the standing and supine positions. It appears that the chart is comparing the effects of Tadalafil 20 mg & doxazosin 8 mg versus a placebo & doxazosin 8 mg on blood pressure at various time points post-dose.*

This is a graph showing the plasma concentration of Tadalafil in ug/L after administration of different doses (20 mg and 5 mg) and regimens (single and once-daily following 5 consecutive days of administration) over a period of 120 hours. The concentration ranges from 0 to 500 ug/L.*

The text describes a graph showing the change in PSS total score for a treatment with Tadalafil 5 mg compared to a placebo. The graph shows a statistically significant difference between the two treatments with a p-value of less than 0.01. The X-axis of the graph represents the duration of treatment in weeks, while the Y-axis shows the change in PSS total score.*

The text describes the change from baseline in IPSS total score after treatment with Tadalafil 5mg compared to a placebo. The results suggest that Tadalafil 5mg has a statistically significant effect in reducing IPSS total score compared to placebo treatment. The duration of treatment is not specified.*

This appears to be a table or graph showing data on the LS mean change from baseline based on weeks of therapy for two different treatments: Tadalafil/Finasteride and Placebo/Finasteride. However, without more context or readable text, it is not possible to provide a more detailed description.*

The text describes the change in the International Prostate Symptom Score (IPSS) Total Score and the Duration of Treatment in weeks for a study involving Tadalafil 5mg and Placebo. The graph shows that Tadalafil 5mg had a statistically significant improvement in IPSS Total Score compared to Placebo after a certain duration of treatment.*